Rozlytrek (entrectinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

	URGENT			
MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES:				

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>PRIMETHERAPEUTICS.COM/NOPP</u>

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY		IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page



Rozlytrek (entrectinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR		
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
Non-small cell lung cancer				
Locally advanced or metastatic solid tur				
Other diagnosis:ICD-	10			
	: PLEASE PROVIDE ALL RELEVANT CLINIC			
PRIOR AUTHORIZATION.	. PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUFFORT A		
Clinical Information:				
Is drug going to be used as part of a cl	inical trial?			
Does the patient have metastatic non	-small cell lung cancer (NSCLC)? 🗆 Yes	□ No Please submit documentation		
Doos the nationt have a metastatic co	lid tumor? □ Yes □ No Please submit	do cum o ntertion		
Does the patient have a metastatic so		accumentation		
Does the patient have a a locally advanced solid tumor for which surgical resection would likely result in severe morbidity? Yes No 				
Is the patient's tumor positive for a N Yes No Please submit docume	TRK1, NTRK2, and/or NTRK3 gene fusior	1?		
□ res □ No Please submit accume	πτατιοπ			
Is the patient's tumor positive for a ROS-1 mutation? Yes No Please submit documentation				
Is the patient Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (is ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours)?				
If requesting Rozyltrek Pellets(entrectinib pellets), please answer the following:				
Does patient have an enteral feeding tube $? \square Yes \square No$ Please submit documentation				
Does patient have an enteral reeding tube ? res No Please submit documentation Does patient have difficulty swallowing? Yes No Please submit documentation				
Does patient have unnearly swallowing: These to not prease submit documentation Does patient does not have other oral tablets or capsules* on their claims profile in the proceeding four months?				
(*however, sprinkles capsules are also OK) \Box Yes \Box No Please submit documentation				
$(10000000, spinikies capsules are also OK_j \square Tes \square NO Please submit accumentation$				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				



Revision Date: 12.1.2023

© 2017–2024 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

Rozlytrek (entrectinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

***Please note:** Not all drugs/diagnoses are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

_ Date: _

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811